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Abstract
Background: To determine whether the functional effects of oral supplementation with Saffron, a natural
compound that proved to be neuroprotective in early age-related macular degeneration, are influenced by
complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) risk genotypes.
Methods: Thirty-three early AMD patients, screened for CFH (rs1061170) and ARMS2 (rs10490924) polymorphisms
and receiving Saffron oral supplementation (20 mg/day) over an average period of treatment of 11 months (range,
6–12), were longitudinally evaluated by clinical examination and focal electroretinogram (fERG)-derived macular
(18°) flicker sensitivity estimate. fERG amplitude and macular sensitivity, the reciprocal value of the estimated fERG
amplitude threshold, were the main outcome measures.
Results: After three months of supplementation, mean fERG amplitude and fERG sensitivity improved significantly
when compared to baseline values (p < 0.01). These changes were stable throughout the follow-up period. No
significant differences in clinical and fERG improvements were observed across different CFH or ARMS2 genotypes.
Conclusions: The present results indicate that the functional effect of Saffron supplementation in individual AMD
patients is not related to the major risk genotypes of disease.
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Age-related macular degeneration (AMD) is a retinal
neurodegenerative disease characterized in its early stage
by large soft drusen and hypo-hyperpigmentation of the
retinal pigment epithelium (RPE). Late AMD, the poten-
tially blinding stage of disease, includes geographic atro-
phy of the RPE (“dry” age-related macular degeneration),
or subretinal neovascular membranes (“wet” age-related
macular degeneration) [1].
AMD is generally considered as a multifactorial disease,
whose development and progression are the results of a
complex interaction between genetic and environmental
risk factors. Both oxidative stress [2] and chronic in-
flammation [3] seem to play a significant role in the patho-
genesis of AMD [4]. Risk factors as smoking [5], aging [6]
or a low antioxidant intake [7] are all associated with in-
creased levels in the outer retina of reactive oxygen species
(ROS) [8] or lipid peroxidation products as malondialdehyde
(MDA), potentially detrimental for photoreceptors integrity
[9]. Many recent results (reviewed in Swaroop et al., 2009)
[10] support the hypothesis that an uncontrolled activation
of the complement system is responsible for the develop-
ment of a retinal chronic inflammatory response, even in
the early stages of the disease [11-14].
Several susceptibility genes have been linked to the devel-
opment or progression of AMD [15-18]. The Y402H poly-
morphism (rs1061170) in the complement factor H (CFH)
gene [19-21], and the A69S polymorphism (rs10490924) in
the Age-Related Maculopathy Susceptibility 2 (LOC387715/
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ARMS2) [22,23] have been shown to be the strongest
genetic factors to confer AMD susceptibility. CFH is the
major inhibitor of the alternative complement pathway
[24] and it has been suggested that a reduction in its
function, leading to inadequate control of complement
driven inflammation, could be responsible for the devel-
opment of a retinal chronic inflammatory response, even
in the early stages of AMD. Further evidences about the
link between CFH and AMD derive from a recent study
by Weissman et al. [25] indicating that CFH could act
as a protective factor against retinal oxidative stress. In
addition, the functional impact of rs1061170 CFH poly-
morphism on the pathophysiology of cone-mediated ret-
inal function in AMD has been recently shown [26].
The function of ARMS2 protein remains partially un-
known. Its involvement in mitochondrial function [27]
and the correlation between ARMS2 polymorphisms and
smoking [28,29] suggest that the gene product is impli-
cated in oxidative stress defence.
While in the early stages of AMD visual acuity can be
well preserved or only minimally reduced, functional ab-
normalities involving photoreceptors and/or postreceptoral
neurons can be well documented by electrophysiological
or psychophysical methods [30-36]. Recently, a random-
ized clinical trial [37], has demonstrated that dietary
supplementation with Saffron is able to improve signifi-
cantly the focal electroretinogram (fERG) estimated retinal
flicker sensitivity in patients with early AMD, suggesting a
neuroprotective effect of Saffron on dysfunctional fERG
generators, namely photoreceptors, and/or bipolar cells.
Further clinical evidence derives from a longitudinal study,
in which a daily oral Saffron administration proved to
be effective in ameliorating the macular function of
early AMD patients, over a follow-up period of one year
[38]. Previous experimental studies [39,40] demonstrated
that Saffron may protect photoreceptors from retinal
stress, preserving both morphology and function through
its antioxidant and anti-inflammatory properties and
probably acting as a regulator of programmed cell death.
Changes in the functional properties of proteins as
CFH or ARMS2, implicated in the control of retinal
inflammation/oxidative mechanisms, could influence or
limit the functional response to a neuroprotective agent
as Saffron. In order to test this hypothesis, we conducted
a longitudinal study in early AMD patients to determine
whether the effect of Saffron supplementation, evaluated
by means of fERG, could be influenced by the two major
AMD risk polymorphisms in CHF and ARMS2 genes.
Methods
Patients
Thirty-three consecutive patients (mean age, 68.4 years;
range, 51–85; 15 men and 18 women) with a diagnosis
of bilateral early AMD were recruited over an interval of
8 months from the outpatient service of the institution.
Each patient underwent standard general and ophthal-
mic examinations. Clinical diagnosis of early AMD was
established by direct and indirect ophthalmoscopy, as
well as retinal biomicroscopy, when any of the following
primary lesions in the macular area (i.e., the area within
an eccentricity of approximately 2 disc diameters from the
fovea) was identified: soft distinct or indistinct drusen;
areas of hyperpigmentation associated with drusen; or
areas of hypopigmentation of the RPE associated with
drusen, without any visibility of choroidal vessels. All
patients met the following inclusion criteria: best corrected
visual acuity of 0.5 or better in the study eye, central fix-
ation (assessed by direct ophthalmoscopy), normal color
vision with Farnsworth D-15 testing, no signs of other
retinal or optic nerve disease and clear optical media.
Eight patients had moderate systemic hypertension. No
other systemic diseases were present. None of the pa-
tients was taking medications (e.g., chloroquine) that are
known to affect macular function or to interfere with
carotenoid absorption. AMD lesions of the study eyes
were graded on stereoscopic fundus photographs, as
previously described [33]. A macular grading scale, based
on the international classification and grading system [1]
was used by a single grader who evaluated the photo-
graphs while masked to subject characteristics and fERG
results. The presence of basic AMD lesions was noted
within each of the nine subfields delimited by a scoring
grid. Fluorescein angiography and macular optical co-
herence tomography (Cirrus spectral domain, Zeiss)
assessment were also performed in all study eyes at the
time of the diagnosis, to confirm the presence of early
AMD lesions, to exclude geographic atrophy or RPE de-
tachment, and to determine at baseline the average retinal
thickness in the macular region. According to the results
of grading, intermediate AMD was diagnosed in all eyes,
[41] with one or more drusen (≥63 μm) and/or focal
hypo-hyperpigmentation within the macular region. The
average number of drusen was 9 (range, 4–22). Focal RPE
abnormalities extending for at least 10% of one of the
middle subfield areas in the macular region were present
in 9 of 30 patients. The research protocols adhered to
the tenets of the Declaration of Helsinki. The study was
approved by the Ethics Committee/Institutional Review
Board of the Catholic University. Written, informed con-
sent was obtained from each study participant after the
purpose and procedures of the study were fully explained.
Treatment and testing schedule
Patients underwent clinical examination and a Focal ERG
(fERG)-derived macular (18°) flicker sensitivity estimate
[37] every three months over an average period of 11
months (range, 6–12) of treatment (saffron 20 mg/day)
and follow-up. fERG amplitude and sensitivity, derived
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from the estimated response amplitude thresholds, were
the main outcome measures.
Clinical and demographic data of the patients are sum-
marized in Table 1. In all patients, a clinical examination,
including visual acuity testing with a calibrated standard
Snellen chart, fundus examination by direct and indirect
ophthalmoscopy, and fERG testing, was performed at
study entry (baseline) and every 90 days of treatment.
Table 1 Demographic, Genetic and Clinical Findings at baseline in Patients with early AMD
Pt.#, gender, age CFH ARMS2 Visual
acuity
Follow-up
duration
Fundus* fERG§(n. of responses at B,V3, V6, V9, V12)
1, F, 52 HT WT 0.8 6 Soft confluent drusen; central subfield 5(B), 5(V3), 5(V6)
2, M, 63 HT WT 0.8 12 Soft confluent drusen and hypopigm.;
central and middle subfield
4(B), 5(V3), 5(V6), 4(V9), 5(V12)
3, M, 70 HT WT 0.7 12 Soft drusen; central subfield 4(B), 4(V3), 4(V6), 5(V9), 5(V12)
4, M, 73 HT WT 0.7 12 Soft drusen; central and middle subfield 1(B), 5(V3), 6(V6), 6(V9), 6(V12)
5, M, 70 HO WT 0.7 12 Soft confluent drusen; central subfield 5(B), 5(V3), 5(V6), 5(V9), 5(V12)
6, M, 73 HT HT 1.0 12 Soft drusen; central subfield 4(B), 5(V3), 5(V6), 6(V9), 6(V12)
7, F, 65 HT WT 0.9 6 Soft drusen; central subfield 4(B), 5(V3), 6(V6)
8, M, 55 HT HO 1.0 12 Soft drusen and hyperpigm.; central subfield 5(B), 5(V3), 6(V6), 6(V9), 6(V12)
9, M, 79 HT WT 0.5 12 Soft drusen and hyperpigm.; middle subfield 1(B), 1(V3), 4(V6), 6(V9), 6(V12)
10, F, 77 WT WT 0.8 12 Soft drusen; middle subfield 4(B), 5(V3), 5(V6), 5(V9), 5(V12)
11, M,75 WT HT 0.7 12 Soft drusen; middle subfield 4(B), 5(V3), 5(V6), 6(V9), 6(V12)
12, F, 70 HT HT 0.7 12 Soft drusen and hyperpigm.; middle subfield 2(B), 2(V3), 1(V6), 3(V9), 3(V12)
13, F, 81 HT WT 0.5 6 Soft drusen; middle subfield 4(B), 4(V3), 4(V6)
14, F, 54 HO HT 0.6 12 Soft confluent drusen; middle subfield 6(B), 6(V3), 6(V6), 5(V9), 6(V12)
15, F, 64 HT HO 1.0 12 Soft drusen and hypopigm.; middle subfield 2(B), 6(V3), 6(V6), 5(V9), 6(V12)
16, M,58 HT WT 1.0 6 Soft drusen; middle subfield 1(B), 5(V3), 5(V6)
17, M,73 HT HT 1.0 12 Soft drusen and hyperpigm.; middle subfield 4(B), 4(V3), 5(V6), 5(V9), 5(V12)
18, M,70 HT WT 1.0 12 Soft drusen and hyperpigm.; central subfield 4(B), 5(V3), 5(V6), 4(V9), 4(V12)
19, F, 71 HO WT 0.6 12 Soft confluent drusen and hypopigm.;
central subfield
6(B), 6(V3), 5(V6), 5(V9), 6(V12)
20, M,61 HO HO 0.5 12 Soft confluent drusen and hypopigm.;
middle subfield
2(B), 6(V3), 5(V6), 6(V9), 6(V12)
21, F, 62 WT WT 0.6 12 Soft drusen; middle subfield 6(B), 6(V3), 6(V6), 6(V9), 6(V12)
22, F, 71 HO WT 1.0 12 Soft drusen; central and middle subfield 4(B), 5(V3), 5(V6), 6(V9), 5(V12)
23, M,68 HT HO 0.8 12 Soft confluent drusen; central and
middle subfield
2(B), 4(V3), 4(V6), 6(V9), 6(V12)
24, M,71 HT HO 1.0 12 Soft confluent drusen; middle subfield 5(B), 6(V3), 6(V6), 6(V9), 5(V12)
25, F, 81 HT HT 0.8 6 Soft drusen; middle subfield 4(B), 6(V3), 6(V6)
26, F, 52 HT HT 0.6 12 Soft drusen; middle subfield 6(B), 6(V3), 6(V6), 6(V9), 6(V12)
27, F, 73 HO WT 1.0 12 Soft drusen and hyperpigm.; middle subfield 3(B), 5(V3), 5(V6), 5(V9), 5(V12)
28, F, 68 HO WT 0.6 12 Soft confluent drusen; central subfield 6(B), 5(V3), 5(V6), 5(V9), 5(V12)
29, F,51 WT WT 0.5 12 Soft drusen; middle subfield 5(B), 6(V3), 6(V6), 6(V9), 6(V12)
30, F, 84 HT HT 0.5 6 Soft drusen and hyperpigm.; central subfield 3(B), 3(V3), 4(V6)
31, F, 63 WT WT 0.7 12 Soft drusen; central and middle subfield 5(B), 6(V3), 6(V6), 6(V9), 5(V12)
32, M,85 WT WT 0.8 12 Soft drusen; central and middle subfield 5(B), 5(V3), 5(V6), 5(V9), 5(V12)
33, F,74 HT WT 0.9 6 Soft drusen and hyperpigm.; middle subfield 5(B), 6(V3), 6(V6)
Follow-up duration (months). *Macular appearance with reference to drusen type, confluence, and location; RPE abnormality type and main location. §Number of
FERG responses that were above noise level (i.e., S/N ratio ≥ 3) at the different modulation depths of the recording protocol; (6) = S/N ratio ≥ 3 at all modulation
depths, (5) = S/N ratio < 3 at the two lowest modulation depths, (4) = S/N ratio < 3 at the three lowest modulation depths, etc., B: baseline V3, V6, V9, V12: months
of supplementation.
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Clinical and fERG examinations were conducted on the
same day, with ophthalmoscopy always performed after
fERG recordings. During the entire period of supple-
mentation, no other systemic pharmacologic treatments
were given. In all cases, compliance was judged to be
satisfactory, since none of the treated subjects refrained,
for any reason, from taking the daily dose of supplement
during the treatment period. No adverse side effects
were reported.
Electrophysiological methods
fERG testing was performed according to a previously
published technique [33]. Briefly, ERGs were elicited by
the LED-generated sinusoidal luminance modulation of
a circular uniform field (diameter, 18°; mean luminance,
80 cd/m2; dominant wavelength, 630 nm), presented at
the frequency of 41 Hz on the rear of a Ganzfeld bowl,
illuminated at the same mean luminance as the stimulus.
This technique was developed according to the indica-
tions of published clinical studies, in which the fERG
response to sinusoidal flicker stimulation was used to
test retinal flicker sensitivity in comparison to psycho-
physical flicker sensitivity in normal and pathologic condi-
tions [42,43]. In the general recording protocol, a series
of fERG responses was collected at different modulation
depths, quantified by the Michelson luminance contrast
formula: 100% × (Lmax − Lmin)/(Lmax + Lmin), where
Lmax and Lmin are maximum and minimum luminance,
respectively, between 16.5% and 93.8% in 0.1- to 0.3-log-
unit steps (16.5%, 33.1%, 44.8%, 63.6%, 77.2%, and 93.8%).
In some patients, the signal-to-noise ratio (S/N) at the
modulation of 93.5% was not large enough to allow
recording of the whole response family. In those cases,
response collection was limited to the highest or the
two highest modulation depths. In Table 1, the number
of responses that were significantly different from the
noise level, collected at every visit, is reported for
each patient.
fERGs were recorded monocularly by means of Ag-AgCl
superficial cup electrodes taped over the skin of the
lower eyelid. A similar electrode, placed over the eyelid
of the contralateral, patched eye, was used as the reference
(interocular ERG), [44]. fERG signals were amplified,
band-pass filtered between 1 and 250 Hz (−6 dB/octave),
sampled with 12-bit resolution, (2-kHz sampling rate),
and averaged. A total of 1600 events (in eight blocks of
200 events each) were averaged for each stimulus condi-
tion. The sweep duration was kept equal to the stimulus
period. Single sweeps exceeding the threshold voltage
(25 μV) were rejected, to minimize noise coming from
blinking or eye movements. A discrete Fourier analysis
was performed off-line to isolate the fERG fundamental
harmonic and estimate its amplitude (in μV) and phase
(in degrees). Component amplitude and phase were also
calculated separately for partial blocks (200-event packets)
of the total average, from which the standard error of
amplitude and phase estimates were derived to test re-
sponse reliability. Averaging and Fourier analysis were also
performed on signals sampled asynchronously at 1.1 times
the temporal frequency of the stimulus, to give an esti-
mate of the background noise at the fundamental compo-
nent. An additional noise estimate at the fundamental
harmonic was obtained by recording responses to a blank,
unmodulated field kept at the same mean luminance as
the stimulus. In all records, the noise amplitudes recorded
with both methods were ≤0.053 μV.
In all subjects, the fERG testing protocol was started
after a 20-minute period of preadaptation to the stimu-
lus mean illuminance. Pupils were pharmacologically
(tropicamide 1%) dilated to 8 to 9 mm. Subjects fixated
(from a distance of 30 cm) on the center of the stimula-
tion field with the aid of a small (15 minutes of arc) fix-
ation mark. A fERG response was first collected at the
maximum modulation depth (93.5%) included in the proto-
col and was evaluated with respect to reliability and S/N
ratio. In all patients, the responses at 93.5% modulation
satisfied the following criteria: standard deviation esti-
mates of <20% (variation coefficient) and 15° for the amp-
litude and phase, respectively, and an S/N ratio ≥4. In
AMD patients having a response S/N ≥8, fERG signals
were also acquired in sequence for six values of modula-
tion depth between 16.5% and 93.5%, presented in an in-
creasing order. For each stimulus modulation depth, fERG
responses were accepted only if their S/N ratio was ≥2. As
described elsewhere [33], fERG log amplitudes were plot-
ted for each patient as a function of log modulation depth.
The resulting function slope was determined by linear
regression. From the same regression line, fERG thresh-
old was estimated from the value of log modulation depth
yielding a criterion amplitude, corresponding to an S/N
ratio of 3 [33].
Genetic analysis
Samples and DNA extraction
All patients signed an informed consent approving the
use of respective specimens for the general/anonymous
research protocol, in keeping with the Declaration of
Helsinki. Genomic DNA was extracted from blood using
High Pure PCR Template Preparation Kits (Roche Diag-
nostic) and quantified by the NanoPhotometer™ (Implen,
Australia).
PCR conditions and HRM acquisition
Primers were designed to amplify small fragments (81 bp
and 58 bp respectively) surrounding the polymorphisms
c.1277 T>C of CFH (rs1061170) and c.205 G>T of ARMS2
(rs10490924): CFH-forward (CFHf) 5′-TTCCTTATTTGG
AAAATGGATATAA-3′ and CFH-reverse (CFHr) 5′-GAT
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GGCAGGCAACGTCTAT-3′; ARMS2forward (ARMSf)
5′-TGTCTTTATCACACTCCATGATCC-3′ and ARMS2
reverse (ARMSr) 5′-GGTAAGCAGAGCTCAGTGTGG-3′.
PCR amplification for CFH single nucleotide poly-
morphism rs1061170 and ARMS2 rs10490924 was
performed in a 96-well plate in the LightCycler® 480
Real-Time PCR System, as already reported in detail [45].
Genomic DNA (~ 90 ng total) was added to 10 μL of
reaction master mix consisting of 1× LightCycler® 480
High Resolution Melting Master containing the propri-
etary ds-DNA saturating binding dye (Roche Diagnostics,
Germany), in a final reaction volume of 20 μL. PCR reac-
tion contained 3.0 mM MgCl2 and 0.15 μM of forward
and reverse primers.
The PCR program started with an initial denaturation
of 10 min at 95°C, continued with 50 cycles of 10 s at
95°C, 15 s at Ta 62/52°C and 10 s at 72°C. To allow the
enrichment of the correct product over any nonspecific
product we applied a touchdown PCR protocol covering
a range of annealing temperature from 62 to52°C. The
annealing temperature is decreased by 0.5°C every cycle.
The touchdown temperature is then used for the remaining
number of cycles.
The amplification step is followed by a final denaturation
and reannealing step by heating to 95°C for 1min and
cooling down to 40°C for 1 min. This pre-hold temperature
ensures that all PCR products have re-associated and en-
courages heteroduplex formation.
For HRM, the plate was heated from 65°C to 95°C
performing 25 acquisitions for 1°C.
HRM analysis
Melting curve analysis was performed using the Light-
Cycler® 480 Gene Scanning software version 1.5 (Roche
Diagnostics, Germany).
The normalization settings were: 69.6 – 70.6°C for the
pre-melting normalization and 76–77°C for the post-
melting normalization for CFH, and 73 – 74°C for the
pre-melting normalization and 80.6–81.6°C for the post-
melting normalization for ARMS2 [45].
The melting temperature shift was performed automat-
ically by the software using a default adjustment value of
5% for all analyses. The sensitivity level was set at 0.3,
which gave sufficiently consistent and robust results. At
each analytical session, unknown samples were matched
with three standard samples: homozygous for the risk
allele C, heterozygous, and homozygous for the allele T
previously genotyped for rs1061170 and rs10490924 by
sequence analysis and by comparison with the CFH and
ARMS2 genomic sequence (GenBank NG_007259 and
NG_011725 respectively).
Using a curve shape-matching algorithm, samples were
automatically clustered into groups and the melting curve
and difference plots were inspected. Significant differences
in the fluorescence in all subsets indicated different
genotypes.
Statistical analysis
From each patient included in the study, one eye, typically
the eye with the best visual acuity, was selected and desig-
nated as the study eye. The data from the study eyes were
included in the statistical analysis. Main outcome variables
were fERG amplitude, fERG function slope, and threshold.
fERG amplitude data underwent logarithmic transform-
ation to better approximate normal distribution. fERG
slope and threshold are reported as log10 values. In all
statistical analyses, standard error and 95% confidence
interval (CI) of the means were used for between-group
comparisons.
In the absence of any previous data on the effect of
AMD risk polymorphisms on fERG amplitude, slope
and threshold after Saffron supplementation, an accur-
ate estimate of the statistical power of the present study
could not be calculated “a priori”.
Electrophysiological results were analyzed by multivari-
ate analysis of variance (MANOVA) for repeated mea-
sures (MANOVA). Dependent variables in the MANOVA
design were fERG log amplitude, fERG threshold and
slope. Stimulus modulation depth, follow-up time and
genotype (wild type, heterozygous and homozygous) were
the independent variables. fERG log thresholds and slopes,
estimated from the corresponding functions, were indi-
vidually determined by considering only responses with
an S/N ≥ 3.
In all the analyses, results with a p < 0.05 were consid-
ered statistically significant.
Results
Table 1 reports the results regarding the genotype distri-
bution for either CFH and ARMS2 polymorphisms in
each patient. We found 27 out of 33 patients (82%) carry-
ing the “C” allele for the CFH gene (20 in the hetero and 7
in the homozygous state, respectively), while only 13 out
of 33 patients (39%) carried the “T” allele in the ARMS2
gene (8 in the hetero and 5 in the homozygous state,
respectively). Visual acuity did not significantly differ
between patients carrying or not the single variants,
alone or in combination. Similarly, age and funduscopic
features were closely matched between the different gen-
etic subgroups. There was no significant variation across
groups in the number or size of drusen as well as in the
extent of RPE abnormalities.
CHF
The results of fERG modulation functions recorded in
wild type, heterozygotes and homozygotes for the CFH
(rs1061170) polymorphism, at baseline and every three
months after starting Saffron supplementation are reported
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in Figure 1. Responses at the lowest modulation value
(16.5%) are not shown because in most patients they were
recordable only after saffron supplementation. There
was an overall increase in fERG amplitude after the first
three months of supplementation followed by stabilization
over the subsequent follow-up period. MANOVA showed
a significant effect of Saffron treatment (F (4, 19) = 3.89;
p < 0.01) and modulation depth (F (4, 19) = 68.4; p < 0.01)
on amplitude. No significant interaction effect between
genotype and Saffron treatment was found comparing
the three different genotype groups.
Figure 2 shows box plots of the distribution of mean
fERG thresholds and slopes (± interquartile and 95 per-
centile ranges) recorded in wild type, hetero and homo-
zygous patients for the CFH (rs1061170) polymorphism,
at baseline and every three months after Saffron supple-
mentation. As shown in the Figure, the mean threshold
decreased (and consequently the reciprocal sensitivity
value increased) in each group of patients after the first
three months of Saffron supplementation. MANOVA
showed a significant effect of Saffron treatment on fERG
threshold (F (4, 20) = 6.2; p < 0.01) but no differences
across genotype groups. Mean fERG slope did not change
significantly throughout the follow-up period.
ARMS2
The results of fERG modulation functions recorded in
wild type, heterozygotes and homozygotes for the ARMS2
(rs10490924) polymorphism, at baseline and every three
months after starting Saffron supplementation are reported
in Figure 3. MANOVA showed a significant effect of
Saffron treatment (F (4, 18) = 6.46; p < 0.01) and modu-
lation depth (F (4, 18) = 62.1; p < 0.01) on amplitude,
and a significant interaction effect between genotypes
carrying “T” variant and modulation depth (F (8, 36) =
2.29; p < 0.05). No significant interaction effect between
genotype and Saffron treatment was found comparing
the three different genotype groups.
Figure 4 shows box plots of the distribution of mean
fERG thresholds and slopes (± interquartile and 95 per-
centile ranges) recorded in wild type, hetero and homozy-
gous patients for the ARMS2 (rs10490924) polymorphism,
at baseline and every three months after Saffron supple-
mentation. Mean threshold decreased (consequently the
reciprocal sensitivity value increased) in each genotype
group after the first three months of Saffron supplemen-
tation. MANOVA showed a significant effect of Saffron
treatment on fERG threshold (F (4, 19) = 6.9; p < 0.01).
No significant differences in terms of threshold changes
were revealed across groups. Mean fERG slope did not
change significantly throughout the follow-up period.
Discussion
In the present study we evaluated whether the functional
effects of Saffron supplementation on retinal function
of early AMD patients could be influenced by CFH or
ARMS2 risk genotypes. The improvement of macular
function after Saffron supplementation, as evidenced by
an increase in retinal flicker sensitivity, did not differ sig-
nificantly between patients who were hetero/homozygous
or those who were not carriers of CHF or ARMS2 poly-
morphisms, indicating that the individual’s response to
Saffron treatment is not dependent on CHF or ARMS2
genotypes. Moreover, Saffron treatment proved to exert
a long term efficacy in all genotypes. The improvement of
macular function observed after three months of Saffron
supplementation, remained stable throughout the 12 months
follow-up in all patients, regardless of genotype.
Figure 1 fERG modulation function in patients carriers of the CFH (rs1061170) polymorphism. Mean fERG amplitudes (± SE) as a function
of modulation depth, at baseline (V0) and after three (V3), six (V6), nine (V9) and twelve (V12) months of Saffron treatment, are represented
separately for wild type (n = 6), heterozygous (n = 20) and homozygous (n = 7) patients for the CFH (rs1061170) polymorphism.
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The Y402H CHF polymorphism is a major genetic risk
factor associated to AMD [46]. CFH represents the major
fluid phase inhibitor of the alternative complement path-
way [47], and therefore has an anti-inflammatory activity.
Any change in CFH regulation can have a profound effect
on the alternative pathway regulation [47] leading to an
uncontrolled activation of the alternative complement
pathway and to the development of a complement driven
inflammation, potentially detrimental for the retinal tissue
[48]. New evidences about the existing link between CHF
and AMD derive from a recent study by Weismann et al.
[25], who have demonstrated that CHF can directly
Figure 2 fERG threshold and slope in patients carriers of the CFH (rs1061170) polymorphism. Box-whiskers plots of fERG threshold and slope
values at baseline (V0) and after three (V3), six (V6), nine (V9) and twelve (V12) months of Saffron treatment, in wild type (n = 6), heterozygous (n = 20)
and homozygous (n = 7) patients, for the CFH (rs1061170) polymorphism. In each diagram the symbol is the mean, the box indicates the median and
interquartile range and bars indicate the 95 percentiles.
Figure 3 fERG modulation function in patients carriers of the ARMS2 (rs10490924) polymorphism. Mean FERG amplitude (± SE) as a function
of the corresponding values of modulation depth, at baseline (V0) and after three (V3), six (V6), nine (V9) and twelve (V12) months of Saffron treatment,
are represented separately for wild type (n = 20), heterozygous (n = 8) and homozygous (n = 5) patients for the ARMS2 (rs10490924) polymorphism.
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protect the retina from oxidative damage and that Y402H
variant is able to increase retinal susceptibility to an in-
flammatory damage induced by oxidative stress. As a
consequence of an altered CHF, fERG generators, i.e.,
photoreceptors and bipolar cells, would be exposed to a
greater inflammatory/oxidative stress resulting more dam-
aged and dysfunctional, as evidenced by a lower fERG
amplitude and retinal sensitivity in patients who are car-
riers of the Y420H polymorphism [26]. This finding is fur-
ther supported by a study of Feigl et al. [49] who showed
that carriers of the Y402H polymorphism, even with a
normal fundus and visual acuity, may have a significantly
lower psychophysical flicker fusion frequency, as com-
pared to normal/low risk genotypes, with mesopic stimu-
lation. In this context, the beneficial functional effects
of Saffron supplementation found in this study, may in-
dicate that the early damaging effect of AMD on the
outer retina, exacerbated by the CFH risk genotypes,
can be significantly counteracted by this approach.
An example of how risk polymorphisms could influ-
ence the efficacy of an antioxidant supplementation in
AMD patients can be found in a recent pharmacogenetic
study by Klein et al. [50]. In this work the authors evalu-
ated the influence of the Y402H CFH and the A69S
ARMS2 polymorphisms on the response to treatment
with Age-Related Eye Disease Study (AREDS) formula-
tion (Zinc, β-carotene, Vitamin C and E), in reducing
risk progression towards advanced stages of AMD. AREDS
supplementation was associated with a greater reduc-
tion in AMD progression (68%) in patients who were
not carriers of the Y402H polymorphism, as compared
with those who were homozygous (11%), indicating
that CFH (rs1061170) can limit significantly the bene-
fits deriving from the AREDS formulation. Conversely,
ARMS2 polymorphism did not influence AREDS indi-
vidual’s response.
The mechanisms by which Saffron exerts its neuro-
protective action on retinal cells are complex and still
under investigation. Preclinical studies have demon-
strated the antioxidant [39,51], anti-inflammatory [52-54]
and antiapoptic [55] properties of this compound. In an
experimental model [40] of photoreceptor light damage
in albino rat retina, Saffron-treated animals showed pres-
ervation of the photoreceptor morphology and function,
as well as a reduced number of apoptotic figures. There is
evidence that Saffron inhibits TNF-α induced apoptosis,
by modulating Bcl-2 family protein expression [55] and
suppresses caspase activation [56]. Therefore, Saffron
Figure 4 fERG threshold and slope in patients carriers of the ARMS2 (rs10490924) polymorphism. Box-whiskers plots of fERG threshold
and slope values at baseline (V0) and after three (V3), six (V6), nine (V9) and twelve (V12) months of Saffron treatment, in wild type (n = 20),
heterozygous (n = 8) and homozygous (n = 5) patients, for the ARMS2 (rs10490924) polymorphism. In each diagram the symbol is the mean, the
box indicates the median and interquartile range and bars indicate the 95 percentiles.
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seems to exert its neuroprotective action on retinal cells
acting on different levels, protecting, upstream, retinal
cells from potential apoptotic stimuli thanks to its
antioxidant and anti-inflammatory properties, and con-
trolling, downstream, directly the apoptosis process, inter-
fering with the intracellular decisional mechanisms that
lead the cell to initiate the apoptotic program.
One of the major limitations of the present study is
represented by the reduced sample size of the patients
that were included, a factor that could account for a low
statistical power. However it should be considered that
is the first study that has tried to quantify in terms of
retinal sensitivity changes, the pharmacogenetic inter-
action between the AMD associated risk polymorphisms
and a treatment with an oral supplementation. It is there-
fore reasonable to consider the present work a preliminary
pharmacogenetic report, and even if larger studies are
needed to confirm its results, it can provide, to our
opinion, useful indications for the design of further
pharmacogenomic association studies in AMD patients.
Conclusion
In conclusion, the results of this study indicate that
Saffron long term efficacy in improving macular func-
tion is rather independent by the two major CFH and
ARMS2 risk polymorphisms related to AMD. This could
have direct implications for the clinical management of
early AMD patients, in whom appropriate neuroprotective
strategies may be critical in preventing the development
of the blinding stage of disease.
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